welcome
CNBC

CNBC

Health

Health

Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

CNBC
Summary
Nutrition label

77% Informative

Demand in the U.S. has far outpaced supply for Eli Lilly’s incretin drugs, such as Zepbound and Mounjaro , over the last year .

The pharmaceutical giant also issued fiscal 2025 profit guidance of $ 22.05 to $ 23.55 per share, which is in line with what analysts were expecting.

VR Score

88

Informative language

95

Neutral language

41

Article tone

formal

Language

English

Language complexity

41

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links